ArticleGut2017
Marine ω-3 polyunsaturated fatty acid intake and survival after colorectal cancer diagnosis.
Article in Gut, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06887673 (Exploring the Impact of Montelukast, SPM, and/or Almond/Almond Oil Supplementation on Lipid Mediator Biosynthesis in Colorectal, Sarcomas, Brain Tumors, Endometrial, and Ovarian Cancer), which is not on this map. Cited by 59 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploring the Impact of Montelukast, SPM, and/or Almond/Almond Oil Supplementation on Lipid Mediator Biosynthesis in Colorectal, Sarcomas, Brain Tumors, Endometrial, and Ovarian Cancer: A Pilot Study
Who cites it
59 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Bibliometric and visual analysis of omega-3 polyunsaturated fatty acids in cancer research (2000-2025).Frontiers in nutrition · 2026Pooled it
- Epigenome-wide association study of dietary fatty acid intake.Clinical epigenetics · 2024Pooled it
- Interplay of chronic obstructive pulmonary disease and colorectal cancer development: unravelling the mediating role of fatty acids through a comprehensive multi-omics analysis.Journal of translational medicine · 2023Pooled it
- Long-term outcomes after perioperative treatment with omega-3 fatty acid supplements in colorectal cancer.BJS open · 2020Trial
- Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance).International journal of cancer · 2019Trial
- The advent of precision nutrigeroscience in cancer: from clinic towards molecular biology.Journal of advanced research · 2026Review
- Progress on the regulation of colorectal cancer and cardio-oncology by the gut microbiota and nutrients.Frontiers in immunology · 2026Review
- The role of gut microbiota and its metabolites in preventing oncogenesis.Frontiers in cell and developmental biology · 2026Review
- The Microbiota-Diet-Immunity Axis in Cancer Care: From Prevention to Treatment Modulation and Survivorship.Nutrients · 2025Review
- The association of dietary fat and fatty acid intake with ovarian cancer survival: findings from the OOPS, a prospective cohort study.Nutrition journal · 2025Article
- The Impact of Polyunsaturated Fatty Acids in Cancer and Therapeutic Strategies.Current nutrition reports · 2025Review
- Article
- Examining the Role of Nutrition in Cancer Survivorship and Female Fertility: A Narrative Review.Current developments in nutrition · 2024Review
- Integrative Oncology Approaches to Reduce Recurrence of Disease and Improve Survival.Current oncology reports · 2024Review
- Glaucoma and dietary links: insights from high-salt intake, the Mediterranean diet, and specific nutrients.Frontiers in nutrition · 2024Review
- The Salmon Oil OmeGo Reduces Viability of Colorectal Cancer Cells and Potentiates the Anti-Cancer Effect of 5-FU.Marine drugs · 2023Article
- Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation.Science advances · 2023Article
- Vitamin C intake and colorectal cancer survival according to KRAS and BRAF mutation: a prospective study in two US cohorts.British journal of cancer · 2023Article
- Review
- Flavonoid intake and survival after diagnosis of colorectal cancer: a prospective study in 2 US cohorts.The American journal of clinical nutrition · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveExperimental evidence supports an antineoplastic activity of marine ω-3 polyunsaturated fatty acids (ω-3 PUFAs; including eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid). However, the influence of ω-3 PUFAs on colorectal cancer (CRC) survival is unknown.
designWithin the Nurses' Health Study and Health Professionals Follow-up Study, we prospectively studied CRC-specific and overall mortality in a cohort of 1659 patients with CRC according to intake of marine ω-3 PUFAs and its change after diagnosis.
resultsHigher intake of marine ω-3 PUFAs after CRC diagnosis was associated with lower risk of CRC-specific mortality (p for trend=0.03). Compared with patients who consumed <0.10 g/day of marine ω-3 PUFAs, those consuming at least 0.30 g/day had an adjusted HR for CRC-specific mortality of 0.59 (95% CI 0.35 to 1.01). Patients who increased their marine ω-3 PUFA intake by at least 0.15 g/day after diagnosis had an HR of 0.30 (95% CI 0.14 to 0.64, p for trend <0.001) for CRC deaths, compared with those who did not change or changed their intake by <0.02 g/day. No association was found between postdiagnostic marine ω-3 PUFA intake and all-cause mortality (p for trend=0.47).
conclusionsHigh marine ω-3 PUFA intake after CRC diagnosis is associated with lower risk of CRC-specific mortality. Increasing consumption of marine ω-3 PUFAs after diagnosis may confer additional benefits to patients with CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.